An­tibi­ot­ic de­vel­op­er scores $50M from biotech bil­lion­aire; Bio­haven's Alzheimer's drug pass­es fu­til­i­ty test

→ An­tibi­ot­ic de­vel­op­er Sum­mit Ther­a­peu­tics has scored a cool $50 mil­lion in fund­ing from biotech bil­lion­aire Robert Dug­gan — the for­mer chief of Phar­ma­cyclics, the …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER